title: Use of biological response modifiers in the treatment of cutaneous T-cell lymphoma.
abstract: Cutaneous T-cell lymphoma (CTCL) is typically a skin-infiltrating, clonal proliferative disorder of CD4+ T cells that exhibit a T-helper type 2 cytokine phenotype. Therapeutic decisions are based on the extent of disease and the observations that host-antitumor responses occur and that these responses may be blunted by the immunosuppressive cytokines produced by the malignant T cells. Biologic response modifiers, which may enhance cell-mediated immunity and antitumor responses, are active agents in the treatment of CTCL. The rationale and use of biologic response modifiers to treat CTCL are reviewed in this article.
authors.affiliation: Department of Dermatology, University of Pennsylvania School of Medicine, Philadelphia 19104, USA.
authors.forename: A H
authors.initials: AH
authors.lastname: Rook
authors.forename: E K
authors.initials: EK
authors.lastname: Yoo
authors.forename: D J
authors.initials: DJ
authors.lastname: Grossman
authors.forename: D M
authors.initials: DM
authors.lastname: Kao
authors.forename: F E
authors.initials: FE
authors.lastname: Fox
authors.forename: Z
authors.initials: Z
authors.lastname: Niu
mesh_terms: D006801:Humans; D007155:Immunologic Factors / Q000627:therapeutic use*; D016410:Lymphoma, T-Cell, Cutaneous / Q000628:therapy*
chemical_list: D007155:Immunologic Factors